EGFR (epidermal growth factor receptor; HGNC:3236, NCBI Gene 1956) is the gene on chromosome 7p11.2 encoding the ErbB1 receptor tyrosine kinase — the transmembrane receptor that binds EGF and transforming growth factor-α, dimerises, and switches on the RAS-RAF-MEK-ERK and PI3K-AKT cascades. Its activating mutations and amplification drive lung adenocarcinoma and glioblastoma, and it is oncology's classic kinase target: gefitinib and erlotinib inside the cell, cetuximab outside.
Approved Symbol
EGFR (HGNC:3236)
Chromosomal Locus
7p11.2
Encoded Product
EGFR/ErbB1 — a 170-kDa receptor tyrosine kinase (1,210 aa)
Lung-cancer driver (exon 19 del, L858R, T790M); TKI and antibody therapy
Gene Structure & Expression
Genomic organization: 28 exons encoding the extracellular ligand-binding domains (exons 5–7 the drug-binding domain III), the transmembrane helix, the juxtamembrane region, and the cytoplasmic kinase domain (exons 18–24) — the exons where the classic lung-cancer mutations cluster.
Expression and regulation: Expressed widely in epithelial tissues; ligand binding induces dimerisation (with ErbB partners or itself) and Cbl-mediated endocytosis down-regulates signaling — the degradation route the v-ErbB viral oncogene shed.
Molecular Function & Pathways
Signal relay: Ligand-induced dimerisation activates the intracellular kinase; trans-autophosphorylation of tyrosine tails creates docking sites for GRB2-SOS (activating RAS) and PI3K — growth and survival commanded from one receptor.
Oncogenic activation: Exon-19 deletions and L858R (lung adenocarcinoma) activate the kinase without ligand; extracellular-domain deletions or rearrangements (EGFRvIII in glioblastoma) constitutively signal; amplification in many epithelial tumors.
Clinical & Therapeutic Significance
Cancer genetics: Sensitizing mutations in 10–15% of Western and ~50% of East-Asian lung adenocarcinomas; EGFR amplification/mutation in glioblastoma, head-and-neck, and colorectal cancer (where anti-EGFR antibodies work only in KRAS-wild-type tumors).
Therapeutics: First-generation TKIs (gefitinib, erlotinib), the T790M-targeting osimertinib (now first-line), and antibodies (cetuximab, panitumumab) — resistance biology (C797S, MET bypass) driving the next generations; rash as the on-target side-effect signature.